Rorer recombinant Factor VIII
Executive Summary
Invitron will supply Rorer with the genetically derived antihemophilic product for early clinical trials. Invitron will also supply between one and two kilograms of monoclonal antibody in 1988 for purification of Rorer's Monoclate plasma-derived Factor VIII.